Brains Bioceutical Targets Nasdaq in $750 Million SPAC Deal

Armada Acquisition Corp. III (AACI ) and Brains Bioceutical Corp. announced on November 5, 2026 a definitive business-combination agreement valuing Brains at approximately $750 million in implied pre-money equity value. The transaction would take the Vancouver-headquartered cannabinoid pharmaceutical company public through a merger with Armada III, a special purpose acquisition company.

The agreement was entered on October 31, 2026. Existing Brains shareholders are expected to roll 100% of their equity into the combined company, which would operate as Brains Therapeutics Corp. Its common shares are expected to trade on Nasdaq, making the proposal a route to a listing rather than a completed public-market debut.

Both companies’ boards unanimously approved the transaction, and Armada III’s sponsor and certain Brains shareholders entered support and lock-up agreements. The companies are targeting a second-quarter 2027 closing, subject to shareholder approvals, an effective transaction registration statement, Nasdaq listing approval, required regulatory approvals and other closing conditions.

Manufacturing Anchors the Proposal

Brains’ operating base is BSPG Laboratories Limited, its wholly owned subsidiary with an MHRA-inspected and registered active pharmaceutical ingredient (API) manufacturing facility in Kent, England. Brains describes the site as one of the world’s largest cannabinoid pharmaceutical API manufacturing facilities. Brains manufactures or develops CBD, D9-THC, D8-THC, CBN and CBG active ingredients, alongside drug intermediates and finished medical products.

The company’s operating profile lists an EDQM Certificate of Suitability for its CBD API, an active US Drug Master File and an EU Active Substance Master File. Brains reports more than 500 GMP batches produced, adding a production record to the regulatory documentation underpinning the transaction’s manufacturing case.

API manufacturing and supply is one of two principal business drivers, complemented by pharmaceutical-grade nutraceutical ingredients and finished branded or white-label products for supplement, beverage and personal-care companies. The second is pharmaceutical research and drug development, complemented by an animal-health business developing cannabinoid medicines and over-the-counter products for companion and performance animals. Brains reports API supply and development relationships with international pharmaceutical and healthcare organizations, though the announcement does not name them or disclose revenue.

Drug Programs Remain at Different Stages

Brains has licensed global commercial rights to an extended-release methazolamide program for glaucoma. Brains reports that a pivotal bioequivalence study conducted under an FDA Special Protocol Assessment found the once-daily extended-release formulation bioequivalent to twice-daily immediate-release methazolamide. Any commercial launch still requires submission and FDA approval of a marketing application and achievement of other development milestones; no launch date was provided.

In opioid use disorder, Brains supplies clinical-trial material to an NIH-funded program, led by an unnamed US institution, that is evaluating a cannabinoid-based treatment. The company reports that the program has received $18 million in NIH funding and is being evaluated in a Phase 3 randomized controlled trial involving approximately 450 subjects across seven sites. Brains holds an exclusive option to negotiate a license to the program’s rights, not an existing license.

Other work includes a proprietary oral capsule formulation for epilepsy and an in-house sleep-disorder development opportunity. The development model combines Brains’ API capabilities and intellectual property with external partnerships, connecting the pipeline to the same manufacturing and regulatory platform at the center of the transaction.

Rick Brar, Brains’ CEO and chairman, linked the proposed listing to the resources needed for that strategy: “We believe becoming a publicly traded company will provide Brains with the capital and market visibility to accelerate the next phase of our development.”

The proposal therefore pairs an operating ingredient manufacturer with a drug portfolio that still has substantial regulatory and licensing steps ahead. Completing the SPAC transaction would establish the public listing; building a broader medicines business depends on FDA decisions, development milestones and, in opioid use disorder, whether Brains converts its option into a license.